The immunomodulatory effects of macrolide antibiotics in respiratory disease.
Azithromycin
Bronchiectasis
COPD
Cystic fibrosis
Neutrophils
Journal
Pulmonary pharmacology & therapeutics
ISSN: 1522-9629
Titre abrégé: Pulm Pharmacol Ther
Pays: England
ID NLM: 9715279
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
23
08
2021
revised:
25
10
2021
accepted:
29
10
2021
pubmed:
7
11
2021
medline:
15
12
2021
entrez:
6
11
2021
Statut:
ppublish
Résumé
Macrolide antibiotics are well known for their antibacterial properties, but extensive research in the context of inflammatory lung disease has revealed that they also have powerful immunomodulatory properties. It has been demonstrated that these drugs are therapeutically beneficial in various lung diseases, with evidence they significantly reduce exacerbations in patients with COPD, asthma, bronchiectasis and cystic fibrosis. The efficacy demonstrated in patients infected with macrolide tolerant organisms such as Pseudomonas aeruginosa supports the concept that their efficacy is at least partly related to immunomodulatory rather than antibacterial effects. Inconsistent data and an incomplete understanding of their mechanisms of action hampers the use of macrolide antibiotics as immunomodulatory therapies. Macrolides recently demonstrated no clinically relevant immunomodulatory effects in the context of COVID-19 infection. This review provides an overview of macrolide antibiotics and discusses their immunomodulatory effects and mechanisms of action in the context of inflammatory lung disease.
Identifiants
pubmed: 34740749
pii: S1094-5539(21)00107-3
doi: 10.1016/j.pupt.2021.102095
pmc: PMC8563091
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Macrolides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102095Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Am J Vet Res. 2002 Jan;63(1):36-41
pubmed: 16206777
Clin Exp Immunol. 1997 Feb;107(2):410-6
pubmed: 9030883
Lancet Respir Med. 2015 Jun;3(6):435-42
pubmed: 25878028
Curr Med Res Opin. 2007 Mar;23(3):515-22
pubmed: 17355733
Lancet Respir Med. 2014 May;2(5):361-8
pubmed: 24746000
Lancet. 2021 Feb 13;397(10274):605-612
pubmed: 33545096
Pediatr Res. 2007 Oct;62(4):483-8
pubmed: 17667842
J Cyst Fibros. 2014 Mar;13(2):148-55
pubmed: 24440167
Eur Respir J. 1999 Jun;13(6):1371-9
pubmed: 10445614
Am J Respir Cell Mol Biol. 2000 Sep;23(3):389-95
pubmed: 10970831
Respiration. 2011;81(1):75-87
pubmed: 20733282
Biochem Biophys Res Commun. 2000 Jan 7;267(1):124-8
pubmed: 10623585
Front Vet Sci. 2018 Apr 11;5:57
pubmed: 29696149
Eur Respir J. 2010 Sep;36(3):646-54
pubmed: 20150207
Cell Death Dis. 2019 Sep 12;10(9):678
pubmed: 31515489
Respirology. 2012 Jul;17(5):802-7
pubmed: 22288725
Biochem J. 2004 Sep 1;382(Pt 2):393-409
pubmed: 15214841
Biomed Pharmacother. 2019 Feb;110:440-448
pubmed: 30530046
JAMA. 2003 Oct 1;290(13):1749-56
pubmed: 14519709
CNS Neurosci Ther. 2019 May;25(5):591-600
pubmed: 30677254
Nihon Kyobu Shikkan Gakkai Zasshi. 1987 Jun;25(6):632-42
pubmed: 3682440
J Antimicrob Chemother. 1989 Oct;24(4):561-72
pubmed: 2559072
Eur Respir J. 2020 Oct 1;56(4):
pubmed: 32366495
Sci Rep. 2014 Dec 11;4:7438
pubmed: 25500904
Lancet Respir Med. 2021 Aug;9(8):873-884
pubmed: 33609487
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16556-61
pubmed: 24062461
Pharmacol Res. 2011 May;63(5):389-97
pubmed: 21315154
JAMA. 2013 Mar 27;309(12):1260-7
pubmed: 23532242
Lancet. 2021 Mar 20;397(10279):1063-1074
pubmed: 33676597
Eur Respir J. 2015 Feb;45(2):428-39
pubmed: 25359346
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S5-11
pubmed: 10556161
Rev Med Virol. 2021 Mar;31(2):e2163
pubmed: 32969125
Microbiol Immunol. 1996;40(7):473-9
pubmed: 8865152
Am J Respir Crit Care Med. 2008 Jan 15;177(2):148-55
pubmed: 17947611
Clin Exp Immunol. 2011 Dec;166(3):385-92
pubmed: 22059997
Antimicrob Agents Chemother. 1993 Sep;37(9):1786-9
pubmed: 8239585
Eur Respir J. 2006 Sep;28(3):486-95
pubmed: 16737992
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462509
Antimicrob Agents Chemother. 2001 Jan;45(1):44-7
pubmed: 11120942
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Eur Respir J. 2006 Jan;27(1):12-9
pubmed: 16387930
Am J Pathol. 1985 Apr;119(1):101-10
pubmed: 2984939
Sci Rep. 2021 Aug 11;11(1):16361
pubmed: 34381155
Front Immunol. 2016 Aug 15;7:311
pubmed: 27574522
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29967025
Cochrane Database Syst Rev. 2018 Mar 15;3:CD012406
pubmed: 29543980
Int J Antimicrob Agents. 2005 Mar;25(3):216-20
pubmed: 15737515
JAMA. 2010 May 5;303(17):1707-15
pubmed: 20442386
Am J Respir Crit Care Med. 2004 Dec 15;170(12):1331-9
pubmed: 15361366
JAMA. 2013 Mar 27;309(12):1251-9
pubmed: 23532241
J Antimicrob Chemother. 2008 Mar;61(3):554-60
pubmed: 18230686
Int Immunopharmacol. 2016 Nov;40:318-326
pubmed: 27664570
Diagn Pathol. 2012 Jun 11;7:65
pubmed: 22686245
Lancet. 2017 Aug 12;390(10095):659-668
pubmed: 28687413
Int J Mol Sci. 2020 Jul 14;21(14):
pubmed: 32674481
Clin Infect Dis. 2012 Aug;55(4):534-42
pubmed: 22573850
PLoS One. 2018 Jul 12;13(7):e0200474
pubmed: 30001416
Eur Respir J. 2006 Oct;28(4):862-71
pubmed: 17012632
Infect Immun. 2010 Jun;78(6):2620-30
pubmed: 20368349
Clin Ther. 2009 Aug;31(8):1754-64
pubmed: 19808134
Eur Respir J. 2017 May 19;49(5):
pubmed: 28526799
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Int J Mol Sci. 2018 Dec 17;19(12):
pubmed: 30563002
Antimicrob Agents Chemother. 2011 Jan;55(1):338-48
pubmed: 20956586
Int J Mol Sci. 2017 Dec 08;18(12):
pubmed: 29292737
Annu Rev Immunol. 1999;17:593-623
pubmed: 10358769
J Antimicrob Chemother. 2002 May;49(5):745-55
pubmed: 12003967
J Antimicrob Chemother. 1996 Jul;38(1):81-93
pubmed: 8858460
Br J Pharmacol. 2017 Sep;174(18):2967-2983
pubmed: 28664582
J Leukoc Biol. 2012 Feb;91(2):229-43
pubmed: 22131344
Int J Antimicrob Agents. 2021 Jan;57(1):106239
pubmed: 33408029
J Antimicrob Chemother. 2000 Aug;46(2):235-40
pubmed: 10933646
Antimicrob Agents Chemother. 1995 Apr;39(4):872-7
pubmed: 7785987
Antimicrob Agents Chemother. 2015 Dec 07;60(2):1040-8
pubmed: 26643338
Postgrad Med. 2017 Jun;129(5):493-499
pubmed: 28116959
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1139-47
pubmed: 18723437
N Engl J Med. 2011 Aug 25;365(8):689-98
pubmed: 21864166
Front Immunol. 2018 Mar 13;9:302
pubmed: 29593707
J Cyst Fibros. 2009 May;8(3):203-10
pubmed: 19345617
Ecancermedicalscience. 2015 Feb 24;9:513
pubmed: 25729426
Thorax. 2020 May;75(5):370-404
pubmed: 32303621
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
Clin Exp Immunol. 2007 Mar;147(3):540-6
pubmed: 17302905
Cell Death Dis. 2018 Oct 22;9(11):1080
pubmed: 30348950
Int J Pediatr Otorhinolaryngol. 2007 Feb;71(2):297-305
pubmed: 17137638
Antimicrob Agents Chemother. 1994 Jul;38(7):1548-54
pubmed: 7979287
Eur J Pharmacol. 2002 Aug 30;450(3):277-289
pubmed: 12208321
Int J Antimicrob Agents. 2020 Oct;56(4):106143
pubmed: 32853672
Chest. 2002 Dec;122(6):2137-45
pubmed: 12475858
Lancet. 2012 Aug 18;380(9842):660-7
pubmed: 22901887
Am J Respir Cell Mol Biol. 2009 May;40(5):519-35
pubmed: 18978300
Lancet Respir Med. 2019 Oct;7(10):845-854
pubmed: 31405828
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
J Antimicrob Chemother. 2000 Jul;46(1):19-26
pubmed: 10882684
Ann N Y Acad Sci. 1996 Oct 31;796:21-9
pubmed: 8906208
Clin Exp Allergy. 2019 Oct;49(10):1306-1320
pubmed: 31183918
Eur Respir J. 1995 Sep;8(9):1451-7
pubmed: 8575568
J Infect Chemother. 2005 Apr;11(2):112-4
pubmed: 15856383
Mediators Inflamm. 2014;2014:708608
pubmed: 25580060
Thorax. 2002 Mar;57(3):212-6
pubmed: 11867823
Int J Clin Pract. 2021 Apr;75(4):e13856
pubmed: 33231925
J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82
pubmed: 2154441
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Lancet Respir Med. 2019 Oct;7(10):855-869
pubmed: 31405826